HENDERSON, NV / ACCESSWIRE / November 29, 2018 / Here are a few biotech/ healthcare and CBD companies that require your attention.
With the holidays upon us and the enormous amount of food consumed between November and January, it's an opportune time to look at America's obesity problem. Obesity costs the US $1.72 Trillion annually between healthcare costs and decreased productivity. Companies with winning remedies to this problem will see their market cap grow like their potential patients' waists.
One interesting company tackling this issue is, BioRestorative Therapies, Inc. (BRTX) (Market Cap: $7.196M Share Price: $0.74) a life sciences company focused on stem cell-based therapies, developing a therapy "ThermoStem" using brown adipose (fat) derived stem cells to generate brown adipose tissue ("BAT"). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans.
BRTX just received a Notice of Allowance on the company's fourth patent for their metabolic ThermoStem program. The company's patents span US, Australia and Japan.
Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. This is a very promising sign for the company.
Cannabis is being studied as a treatment for several conditions. Cannabis company, MedMen Enterprises, Inc. (MMNFF) (Market Cap: $1.468B Share Price: $3.31) announced the company's $120 million financing is set to close on December 4th. This deal should help the company add to its growing base of 19 licensed legal marijuana facilities. The company calls itself "the most dominant cannabis enterprise in the emerging legal marijuana industry" and is also one of the nation's largest financial supporters of progressive marijuana laws.
Vertically integrated cannabis company, Curaleaf Holdings, Inc. (LDVTF) (Market Cap: $2.68B Share Price: $5.75) just announced their third quarter results. During the third quarter, Curaleaf saw its revenue surge by 289 percent on a year-on-year basis to $21.4 million. The company's bottom line swung to a net loss of $33.7 million from a net profit of $500,000 a year earlier. The net loss was impacted by a $25 million one-time, non-cash, accounting entry, which was part of the company's reverse takeover. Curaleaf's gross profit, excluding the impact of biological assets, amounted to $13.8 million, an increase of 360 percent on the year.
Another healthcare stock like BRTX to pay attention to Arsanis, Inc. (ASNS). (Market Cap: $43.376M Share Price: $3.03) went parabolic Tuesday after announcing that they have entered into a definitive merger agreement with privately-held X4 Pharmaceuticals under which X4 Pharmaceuticals is expected to merge with a wholly-owned subsidiary of Arsanis in an all-stock transaction. The merger would result in a combined company operating under the X4 Pharmaceuticals name that will focus on the development and commercialization of X4's lead product candidate, X4P-001, and the advancement of X4's pipeline of treatments for rare diseases of the immune system and rare cancers.
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics designed to improve immune cell trafficking to treat rare diseases and cancer.
Exelixis, Inc. (EXEL) (Market Cap: $5.73B Share Price: $19.18) recently announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) tablets as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. This approval allows for the marketing of CABOMETYX in this indication in all 28-member states of the European Union, Norway and Iceland.
This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to received a $90,000 convertible note with the issuer for 90 days of service dated 7/10/18. Regal Consulting has signed an amendment to the agreement dated 7/10/18, to extend the agreement and provide additional services for an additional $80,000 convertible note with the issuer. Regal Consulting has signed a second amendment to add additional services for an additional $90,000 convertible note. All payments were made directly by BioRestorative Therapies, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. BRTX was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
Microspeculators.com Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: Regal Consulting, LLC